Metformin does not appear to cause kidney stones, and laboratory research hints it might actually protect against them. But the relationship is tangled by the fact that the people most likely to take metformin, those with type 2 diabetes, already face a higher risk of kidney stones because of the metabolic changes that come with insulin resistance. Separating the drug’s effects from the disease’s effects has proven difficult, and the human evidence so far is surprisingly thin given how widely metformin is prescribed.
Why Diabetes Itself Puts You at Higher Risk for Stones
Before asking what metformin does, it helps to understand what diabetes does. Insulin resistance, the hallmark of type 2 diabetes, changes your kidney’s handling of several substances that influence stone formation. One of the most studied effects is on urine pH. When cells resist insulin’s signals, the kidney tends to produce more acidic urine, and acidic urine is the primary driver of uric acid stones. Multiple studies have linked metabolic syndrome and insulin resistance to a higher prevalence of uric acid stones specifically.1PubMed Central. Role of insulin resistance in uric acid nephrolithiasis
Insulin resistance also affects citrate, a natural stone inhibitor. Citrate in your urine binds to calcium and prevents it from crystallizing into stones. Research on calcium stone formers found that people with higher levels of insulin resistance excreted significantly less citrate in their urine, and those with the lowest citrate levels had the most insulin resistance.2PubMed. Insulin resistance and low urinary citrate excretion in calcium stone formers So diabetes creates a double problem: more acidic urine favoring uric acid stones, and less citrate to guard against calcium stones. Anyone taking metformin is almost certainly dealing with one or both of these metabolic shifts before the first pill.
What Happens in Lab and Animal Studies
In controlled experiments where you can isolate metformin’s effects from diabetes itself, the drug looks surprisingly protective. One animal study found that rats given an agent that normally causes kidney crystals developed significantly fewer crystal deposits when they were also given metformin. The researchers attributed this to metformin’s antioxidant properties, which protected the cells lining the kidney tubules from the kind of damage that lets crystals anchor and grow.3PubMed Central. Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo
A more recent study went further, showing that metformin not only reduced calcium oxalate crystal deposits in rat kidneys but also shifted the type of crystals that formed. Calcium oxalate comes in two forms: monohydrate, which is thermodynamically stable and sticks stubbornly to tissue, and dihydrate, which is less stable and easier for the body to flush out. Metformin pushed the balance toward the less dangerous dihydrate form. It also protected kidney cells from the oxidative injury and mitochondrial damage that oxalate exposure normally causes.4Archives of Biochemistry and Biophysics. Metformin ameliorates calcium oxalate crystallization and stone formation by activating the Nrf2/HO‐1 signaling pathway
These findings are genuinely interesting and consistent across multiple research groups, but they come with an obvious caveat. Rat kidneys and cell cultures are not the same as human bodies dealing with diabetes, varying diets, and other medications. The leap from “reduced crystal deposits in rats” to “prevents stones in people” remains unproven.
What Human Studies Actually Show
When researchers look at actual patients, the picture gets murkier. A study of over 500 stone-forming patients, about a third of whom had diabetes, found that diabetic patients on metformin had worse urinary profiles than non-diabetic patients. Their urine pH was roughly a third of a unit lower, even after adjusting for blood sugar control and other health conditions.5Canadian Urological Association Journal. Is metformin use associated with changes in urinary parameters in stone formers? Lower pH means more acidic urine, which is a risk factor for uric acid stones.
But here is the key finding that too often gets lost when people worry about metformin: when the researchers compared diabetic patients taking metformin against diabetic patients not taking metformin, there were no significant differences in any urinary parameter. Not pH, not calcium, not oxalate, not citrate, nothing. The worse urinary profile tracked with having diabetes, not with taking metformin.5Canadian Urological Association Journal. Is metformin use associated with changes in urinary parameters in stone formers?
A separate retrospective study that tracked the same patients before and after they started metformin reinforced this conclusion. Researchers compared 24-hour urine collections done before metformin was prescribed with collections done after patients had been on the drug. The supersaturation levels for calcium oxalate, calcium phosphate, and uric acid all stayed essentially unchanged. Urine pH did not budge. The only parameter that changed significantly was urine volume, which increased slightly from about 2.1 to 2.2 liters per day. And when the researchers split patients into lower and higher dose groups, they found no dose-related effect on any urinary parameter.6SpringerOpen. Comparison of 24-Hour urine parameters before and after initiation of Metformin in patients with diabetes and urolithiasis
That small bump in urine volume is worth noting because higher urine volume is generally considered protective against stones; it dilutes the substances that crystallize. But the increase was modest, and the researchers did not attribute it specifically to metformin rather than to the dietary counseling that often accompanies a diabetes diagnosis.
Why the Animal and Human Findings Seem to Disagree
It is tempting to look at the animal data showing protection and the human data showing no clear effect and conclude that one of them must be wrong. The reality is probably simpler: they are measuring different things under different conditions. Animal experiments use healthy animals without diabetes and give them metformin alongside a chemical that forces crystal formation. That isolates the drug’s direct biochemical effects on kidney cells. Human studies, by contrast, involve people who already have diabetes and all the metabolic baggage it carries. Any protective effect of metformin on the kidney tissue level may be drowned out by the unfavorable urinary chemistry that insulin resistance creates.
There is also the question of what counts as an outcome. Animal studies look at crystal deposits in kidney tissue. Human studies tend to measure urinary chemistry and stone events. It is theoretically possible that metformin protects kidney cells from crystal adhesion (as the rat studies suggest) without meaningfully changing the concentrations of stone-forming substances in urine. If that is the case, you would not see it in 24-hour urine panels, which is exactly what the human studies rely on. Researchers have not yet designed a human trial that can test whether metformin users form fewer stones over time compared to diabetic patients on other medications, and that kind of study would take years and thousands of participants.
Metformin’s Anti-Inflammatory and Antioxidant Effects
Part of the reason researchers keep investigating metformin for kidney stones is that the drug has well-documented effects on inflammation and oxidative stress, both of which play roles in stone formation. Kidney stones are not just a plumbing problem of too much mineral in too little liquid. The process of crystal formation injures kidney tissue, which triggers inflammation, which makes the tissue stickier for more crystals. Breaking that cycle could, in theory, slow stone growth even without changing urinary chemistry.
Research in obese type 2 diabetic patients has shown that metformin treatment is associated with lower levels of several inflammatory markers. Patients on metformin showed reduced activity of a key inflammatory signaling pathway, including drops in molecules that recruit immune cells to sites of tissue injury.7PubMed Central. Systemic Oxidative Stress and Visceral Adipose Tissue Mediators of NLRP3 Inflammasome and Autophagy Are Reduced in Obese Type 2 Diabetic Patients Treated with Metformin Whether this general anti-inflammatory effect translates to meaningful protection in the kidney specifically remains unclear, but it aligns with the animal data showing that metformin shields kidney cells from oxidative damage during crystal formation.
Gut Bacteria and Oxalate
A less obvious connection between metformin and kidney stones runs through the gut. Metformin is known to substantially reshape the composition of gut bacteria. A study in mice found that metformin altered the abundance of roughly 100 bacterial species in animals fed a high-fat diet, with most species increasing in number. The effect was more pronounced in females than in males.8Frontiers in Endocrinology. Metformin Strongly Affects Gut Microbiome Composition in High-Fat Diet-Induced Type 2 Diabetes Mouse Model of Both Sexes
Why would gut bacteria matter for kidney stones? Certain gut microbes, most famously Oxalobacter formigenes, break down oxalate in the intestine before it can be absorbed into the bloodstream and filtered by the kidneys. If metformin encourages the growth of oxalate-degrading bacteria, it could reduce the amount of oxalate reaching the kidneys. If it happens to suppress those bacteria, it could do the opposite. At this stage, no one has connected metformin’s specific microbiome changes to oxalate handling in a way that would let us say whether the net effect is helpful, harmful, or irrelevant for stone risk. It is an active area of research, but one that has not produced actionable findings yet.
Kidney Function Limits and Safety
For people who already have kidney stones, one practical concern is whether metformin itself is safe for kidneys that may have reduced function. Stone disease sometimes coexists with impaired kidney filtration, whether from repeated obstruction, infection, or the underlying metabolic problems that caused the stones in the first place. Metformin is cleared by the kidneys, and when kidney function drops too low, the drug can accumulate and cause a dangerous condition called lactic acidosis.
Current guidelines set clear thresholds based on the estimated filtration rate (eGFR). Metformin is considered safe when the eGFR is above 45. Between 30 and 45, the drug should not be newly started, and anyone already taking it should have their dose capped at 1,000 mg per day. Below 30, metformin is contraindicated entirely.9PubMed Central. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease These cutoffs exist because of the lactic acidosis risk, not because of any stone-related concern. But they are relevant for stone formers because some people with recurrent stones do develop reduced kidney function over time, and their ability to use metformin could be limited as a result.
If you are a stone former with diabetes and your kidney function sits in the borderline range, your doctor will likely monitor your eGFR more frequently while you are on metformin. Staying well hydrated is standard advice for both kidney stone prevention and for reducing the already-low risk of metformin-related kidney problems.
Should Stone Formers Worry About Taking Metformin?
The short answer based on available evidence is no. Nothing in the human data suggests metformin makes stone disease worse. The unfavorable urinary chemistry seen in metformin users tracks with their diabetes, not the medication. The before-and-after study found that starting metformin did not change stone-relevant urine measures in any significant way, regardless of dose.6SpringerOpen. Comparison of 24-Hour urine parameters before and after initiation of Metformin in patients with diabetes and urolithiasis If anything, the animal research suggests metformin may have protective properties that we are not yet able to capture in clinical studies.
The much bigger concern for stone-forming diabetic patients is managing the metabolic environment that diabetes creates. Acidic urine, low citrate, and sometimes elevated uric acid are the real drivers, and those need to be addressed directly through hydration, dietary changes, and sometimes medications like potassium citrate. Metformin’s primary benefit remains blood sugar control, and good glucose management itself may help moderate some of the urinary abnormalities linked to insulin resistance, even if the drug does not directly fix them.
Common Misconceptions Worth Clearing Up
One persistent misunderstanding is the idea that because metformin is processed by the kidneys, it must be hard on them and therefore bad for people prone to stones. Metformin does not damage kidneys. The reason it is restricted in low kidney function is that the kidneys cannot clear it fast enough, allowing it to build up in the blood. That is a concern about the drug’s own toxicity at high concentrations, not about it harming kidney tissue. In people with normal or mildly reduced kidney function, metformin is well tolerated.
Another misconception is that any medication affecting urine composition must change stone risk. Metformin does cause some gastrointestinal side effects that can lead to mild dehydration if fluid intake does not keep up, particularly during the first few weeks of treatment. Dehydration concentrates the urine and raises stone risk. But this is a side effect management issue, not a pharmacological one. Drinking enough water while adjusting to metformin’s GI effects handles it.
Where the Research Stands
The honest assessment is that we are in a genuinely frustrating middle ground. Animal and cell-culture work consistently shows metformin protecting against crystal formation through antioxidant and cell-protective mechanisms. Human studies consistently show no measurable effect on the urinary parameters that clinicians use to assess stone risk. No large prospective trial has followed diabetic patients on metformin versus other diabetes drugs and compared actual stone formation rates over years. Until that kind of study happens, we are left with suggestive lab evidence pointing one direction and clinical data that is essentially silent.
Researchers interested in metformin for stone prevention in non-diabetic patients face an even larger evidence gap. Nearly all the human data comes from diabetic populations, because those are the people prescribed metformin. Whether metformin could be useful as a preventive treatment in stone formers who do not have diabetes is purely speculative at this point. The animal data provides a rationale for studying it, but the clinical pathway from “interesting mechanism” to “recommended therapy” is long and full of treatments that looked promising in rats but did nothing for people.